Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 23INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 464Neoplasms 287Breast Neoplasms 287Colorectal Neoplasms 201Neoplasm Metastasis 178Prostatic Neoplasms 165Ovarian Neoplasms 159Multiple Myeloma 153Lung Neoplasms 150Recurrence 125Melanoma 116Pancreatic Neoplasms 109Stomach Neoplasms 99Squamous Cell Carcinoma of Head and Neck 98Leukemia, Myeloid, Acute 96Endometrial Neoplasms 90Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 83Small Cell Lung Carcinoma 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 78Lymphoma, Large B-Cell, Diffuse 76Carcinoma, Hepatocellular 75Urinary Bladder Neoplasms 72Lymphoma, Follicular 69Advanced Solid Tumors 61Parkinson Disease 4, Autosomal Dominant Lewy Body 60Lymphoma 59Glioblastoma 55Uterine Cervical Neoplasms 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Cognitive Dysfunction × 90 days × Clear all
NCT05637801 2026-05-05

HOPE

Cognito Therapeutics, Inc.

Phase NA Active not recruiting
670 enrolled
Lymphoid

Alzheimer disease type 1, Alzheimer disease type 2, Alzheimer disease type 4, Alzheimer disease, familial, type 3, Alzheimer Disease 9, Alzheimer Disease 8, Alzheimer Disease 11, Alzheimer Disease 7, Alzheimer Disease 6, Alzheimer Disease 10, Alzheimer Disease 5, Alzheimer Disease 15, Alzheimer Disease 14, Alzheimer Disease 13, Alzheimer Disease 12, Alzheimer Disease 16, Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT07563777 2026-05-04

100-Year Human Aging Study

Longevity Metrics, Inc.

Recruiting
10,000 enrolled

Frailty, Cardiovascular Diseases, Dementia, Musculoskeletal Diseases, Neoplasms, Metabolic Syndrome, Cognitive Dysfunction

NCT06745583 2026-04-09

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Phase 2 Recruiting
15 enrolled
Lymphoid

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡